The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Dynamic molecular changes with VEGF targeted therapy in metastatic clear cell renal cancer.
Thomas Powles
Consultant or Advisory Role - GlaxoSmithKline; Pfizer
Research Funding - GlaxoSmithKline; Pfizer
Kevin Sharpe
No relevant relationships to disclose
Dan Berney
No relevant relationships to disclose
Irfan Kayani
No relevant relationships to disclose
Rukma Doshi
No relevant relationships to disclose
Grant Duncan Stewart
No relevant relationships to disclose
Andrew Reynolds
No relevant relationships to disclose
Axel Bex
Consultant or Advisory Role - Pfizer
Research Funding - Pfizer
Naveed Sarwar
No relevant relationships to disclose
Simon Chowdhury
Consultant or Advisory Role - GlaxoSmithKline; Pfizer